A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs VBP 926 (Primary)
- Indications Paronychia
- Focus Therapeutic Use
- Sponsors Veloce BioPharma
- 01 Dec 2017 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 27 Oct 2017 Status changed from not yet recruiting to recruiting.
- 13 Jul 2017 New trial record